Tenon Medical Files S-1/A Amendment

TL;DR

Tenon Medical filed an S-1/A, looks like they're prepping for a stock offering. Keep an eye on this one.

AI Summary

Tenon Medical, Inc. filed an S-1/A amendment on September 9, 2024, for its registration statement (No. 333-281531). The filing pertains to the company's intention to offer securities, though specific details on the number of shares or pricing are not yet provided in this amendment. The company is based in Los Gatos, California, and operates in the surgical and medical instruments sector.

Why It Matters

This filing indicates Tenon Medical is moving forward with plans to raise capital through a public offering, which could impact its future growth and operations.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it indicates a company is preparing to go public or conduct a secondary offering, which inherently carries market and execution risks.

Key Numbers

• 333-281531 — SEC Registration Number (Identifies this specific securities registration)
• 104 — Public Document Count (Indicates the volume of documents associated with this filing)

Key Players & Entities

• Tenon Medical, Inc. (company) — Registrant
• September 9, 2024 (date) — Filing Date
• 333-281531 (registration_number) — SEC Registration Number
• Los Gatos, CA (location) — Company Headquarters
• Steven M. Foster (person) — Chief Executive Officer and President

FAQ

Key Financial Figures

• $0.001 — 8 shares of our common stock, par value $0.001 per share, together with common warrant
• $3.512 — sumed combined public offering price of $3.512 per share and accompanying Common Warra
• $0.0001 — mmon stock and has an exercise price of $0.0001 per share. The Pre-Funded Warrants will
• $4.2756 — mon stock at an exercise price equal to $4.2756 per share for an aggregate offering pri
• $550,000 — hare for an aggregate offering price of $550,000. Each share of Series B Preferred Stock
• $5.09 — r common stock at a conversion price of $5.09 per share, subject to adjustment. The S
• $6.3625 — Agreement, each Series B Investor paid $6.3625 for each share of Series A Preferred St

Filing Documents

• ea0213566-s1a1_tenon.htm (S-1/A) — 2714KB
• ea021356601ex1-1_tenon.htm (EX-1.1) — 62KB
• ea021356601ex3-3_tenon.htm (EX-3.3) — 12KB
• ea021356601ex4-1_tenon.htm (EX-4.1) — 86KB
• ea021356601ex4-2_tenon.htm (EX-4.2) — 96KB
• ea021356601ex5-1_tenon.htm (EX-5.1) — 14KB
• ea021356601ex21-1_tenon.htm (EX-21.1) — 1KB
• ea021356601ex23-1_tenon.htm (EX-23.1) — 3KB
• ea021356601ex23-2_tenon.htm (EX-23.2) — 2KB
• image_001.jpg (GRAPHIC) — 8KB
• image_002.jpg (GRAPHIC) — 14KB
• image_003.jpg (GRAPHIC) — 5KB
• image_004.jpg (GRAPHIC) — 10KB
• image_005.jpg (GRAPHIC) — 28KB
• image_006.jpg (GRAPHIC) — 5KB
• image_007.jpg (GRAPHIC) — 28KB
• image_008.jpg (GRAPHIC) — 9KB
• image_009.jpg (GRAPHIC) — 6KB
• image_010.jpg (GRAPHIC) — 5KB
• image_011.jpg (GRAPHIC) — 11KB
• image_012.jpg (GRAPHIC) — 4KB
• image_013.jpg (GRAPHIC) — 7KB
• ex5-1_001.jpg (GRAPHIC) — 18KB
• ex23-2_001.jpg (GRAPHIC) — 6KB
• ex23-2_002.jpg (GRAPHIC) — 5KB
• 0001213900-24-076697.txt ( ) — 9928KB
• tnon-20240630.xsd (EX-101.SCH) — 68KB
• tnon-20240630_cal.xml (EX-101.CAL) — 56KB
• tnon-20240630_def.xml (EX-101.DEF) — 372KB
• tnon-20240630_lab.xml (EX-101.LAB) — 656KB
• tnon-20240630_pre.xml (EX-101.PRE) — 385KB
• ea0213566-s1a1_tenon_htm.xml (XML) — 912KB

DILUTION

DILUTION 49 MARKET FOR COMMON EQUITY ANDF RELATED STOCKHOLDER MATTERS 51 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 53

BUSINESS

BUSINESS 63 MANAGEMENT 82 EXECUTIVE COMPENSATION 88 PRINCIPAL STOCKHOLDERS 97 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 98 DESCRIPTION OF SECURITIES 98 PLAN OF DISTRIBUTION 116 EXPERTS 118 CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 118 LEGAL MATTERS 119 WHERE YOU CAN FIND MORE INFORMATION 119 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus or any prospectus supplement or amendment. Neither we, nor the placement agent, have authorized any other person to provide you with information that is different from, or adds to, that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the placement agent take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information contained in this prospectus, or any free writing prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of any securities in any jurisdiction in which such offer is unlawful. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this public offering and the distribution of this prospectus applicable to that jurisdiction. i ABOUT THIS PROSPECTUS Throughout this prospectus, unless otherwise designated or the context suggests otherwise, all references to the "Tenon," the "Company," the "regist

View Full Filing

View this S-1/A filing on SEC EDGAR